News, Events & Resources
There’s a lot happening at Melinta. We are the company of the moment and enterprise of the future. Join us in realizing our vision — this is our story, and it’s going to be legendary.
Melinta Joins NHIA Future of Infusion Advisory Council
For Melinta, membership in the FIAC provides the opportunity for critical collaboration with the association and other organizations serving patients requiring infusion therapies. This work helps to enhance continuity of care as patients transition out of the hospital.
Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial & Phase 2 STRIVE Trial of REZZAYO® (rezafungin for injection) for the Treatment of Candidemia & Invasive Candidiasis in The Lancet ID
December 5, 2023 Publication reaffirms the proven efficacy and safety of rezafungin dosed once-weekly versus a current standard of care echinocandin dosed once-daily PARSIPPANY, NJ,
Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.
November 9, 2023 Press Release Parsippany, N.J., and Malvern, PA -- November 9, 2023 — Melinta Therapeutics LLC (“Melinta”) and Venatorx Pharmaceuticals, Inc. (“Venatorx”), today announced that
Melinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023
October 11, 2023Press Release PARSIPPANY, N.J.–Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses,